Agnico-Eagle Mines Ltd. (NYSE: AEM) Cut to Hold at Canaccord Genuity.
Avalon Rare Metals Inc. (AMEX: AVL) Started as Buy at Citigroup.
Brocade Communications Systems Inc. (NASDAQ: BRCD) Reiterated Hold at Argus.
Coinstar, Inc. (NASDAQ: CSTR) Raised to Overweight at JPMorgan.
Eaton Vance Corporation (NYSE: EV) Cut to Underperform at Credit Suisse.
Electronic Arts Inc. (NASDAQ: ERTS) Raised to Buy at Citigroup.
The Finish Line, Inc. (NASDAQ: FINL) named Value stock of the day at Zacks.
Gilead Sciences Inc. (NASDAQ: GILD) Raised to Conviction Buy List at Goldman Sachs.
Google Inc. (NASDAQ: GOOG) Raised to Buy at Citigroup.
Green Dot Corporation (NYSE: GDOT) Started as Outperform at KBW.
Montpelier Re Holdings (NYSE: MRH) named as Bear of the Day at Zacks.
Research in Motion Ltd. (NASDAQ: RIMM) Cut to Neutral at Stern Agee.
Salix Pharmaceuticals (NASDAQ: SLXP) named as Bull of the Day at Zacks.
The Wendy’s Co. (NYSE: WEN) Reiterated Hold at Argus.
Wynn Resorts Ltd. (NASDAQ: WYNN) Raised to Buy at KeyBanc.

Your email address

subscribe

terms and conditions

JON C. OGG

Calumet Specialty Partners Products Limited (NASDAQ: CLMT) is down 6.5% premarket to $21.09, relative to a 52-week range of $14.00-$24.95. The company is issuing a public offering of 4.5 million stocks.

E TRADE Financial Corporation (NASDAQ: ETFC) is down 5.4% premarket on heavy volume to $15.75, relative to a 52-week range of $11.15-$19.90. Citadel Equity Fund announced they would be selling nearly 24 million shares.

Salix Pharmaceuticals (NASDAQ: SLXP) is down 23% to $31.65, relative to a 52-week range of $27.77-$49.05. The company expects the FDA to deny immediate approval of Xifaxan.

We have included the news summaries, price reactions, and have given some added color on each where applicable.

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) is trading up and recovering some of its losses from the peak of the last year after it announced that Dr. Friedman will present additional data demonstrating that pimavanserin was safe and well tolerated for Parkinson’s Disease psychosis at the 62nd American Academy of Neurology Annual Meeting.  Shares are up 7.4% at $1.89 on 2.4 million shares.  Average volume is only 582,000 shares and the 52-week range is $0.88 to $6.60. UPDATE FOR CLOSE: shares closed at $1.77, up only 0.57% on over 3.9 million shares.

Adeona Pharmaceuticals, Inc. (AMEX: AEN) is considerably higher after it announced positive results of part 1 of its CopperProof-2 study in Alzheimer’s Disease patients and noted mild cognitive impairment.  Shares have a new 52-week high of $2.70, and the stock is up a sharp 41% at $2.15.  Even after today’s gains it has a mere $46.6 million market cap. UPDATE FOR CLOSE: shares closed up 24.3% at $1.89 on 10.7 million shares.

CombinatoRx, Incorporated (NASDAQ: CRXX) is up after it announced the discovery of a novel multi-target mechanism to treat hematologic malignancies.  Shares are up 6% at $1.41 on 3.2 million shares.  The average volume is 2.5 million shares and the 52-week trading range is $0.49 to $2.60. UPDATE FOR CLOSE: shares closed at $1.38, up 3.76% on 4.8 million shares.

Dendreon Corporation (NASDAQ: DNDN) has managed to recover and is in positive territory after the stock downgraded by Citigroup on valuation and the target is $40.00.  Shares are up 0.26% at $38.93 and the stock has traded as low as $38.17 early this morning. UPDATE FOR CLOSE: shares closed at $39.12, up 0.75% on 3.73 million shares.

Exact Sciences Corp. (NASDAQ: EXAS) sold 4,200,000 shares of common stock at a price of $4.50 per share in a public secondary offering to receive net proceeds of about $17.6 million after fees. The funds are going to the company and it is still seeking to obtain FDA clearance of its sDNA colorectal cancer screening product.  Shares closed at $4.69 yesterday and the stock is down 3.4% at $4.53 on over 400,000 shares.  The average volume is only 173,000 shares per day and this was at $4.85 5 trading days ago. UPDATE FOR CLOSE: shares closed at $4.53, down 3.4% at $4.53.

InterMune, Inc. (NASDAQ: ITMN) is hardly reacting to what looked like positive news.  The company reported that its top-line results from a Phase IIb study of Danoprevir in patients with chronic Hepatitis C were among the very best reported by any DAA compound to date.  The news sounded big but the stock reaction is muted…. up 0.67% at $48.25 on only 600,000 shares.  The 52-week range is $10.48 to $49.05, so there has already been much movement ahead of the news.  Average volume is 2.4 million shares.  UPDATE FOR CLOSE: shares closed at $48.14, up 0.44% on only 1.3 million shares.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) was the biggest winner of all on Tuesday with a gain of  over 100% as we had noted as a “chasing 10-baggers” example of biotech investors running up stocks on positive cancer news.  Shares are giving back a sharp 20% at $2.76 on continued profit taking and a rethinking of the huge move.  Two days ago this was a $1.50 stock, yet yesterday’s high was an amazing $4.49 and the 52-week range is $1.05 to $7.90.  UPDATE AT CLOSE: My-pie closed down 16% at $2.88 on 3.1 million shares.

Orexigen Therapeutics, Inc. (NASDAQ: OREX) is recovering again from the lows today after shares dropped from over $5.80 to under $5.00 before stabilizing yesterday on news that it was revising data on its obesity drug.  Today’s gain so far is up 3.9% at $5.30 on about 450,000 shares versus and average volume of about 550,000 shares. UPDATE FOR CLOSE: shares closed at $5.51, up 4% on 1.29 million shares.

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) has announced that its formal earnings report will be released on April 22, 2010 after the markets closes.  This alone does not matter, but the pending Astellas hostile tender offer is April 23, 2010.  As noted last week, some trades and bets are being made that the premium above the $52.00 will not be justified in today’s prices.  UPDATE FOR CLOSE: shares closed at $60.00, up 0.4% on only 718,000 shares.

Rexahn Pharmaceuticals, Inc. (AMEX: RNN) is trading up after it issued additional comments and some clarifications on its phase IIa study results of serdaxin in major depressive disorder.  Shares are up over 10% at $1.95 on 8.77 million shares.  The 52 week range is $0.40 to $3.68 and the average volume is just under 2 million shares. UPDATE FOR CLOSE: shares closed up 22% at $2.15 on almost 15.3 million shares.

Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) is trading higher on analyst coverage as the stock was initiated with an ‘Overweight’ rating by Thomas Weisel.  Shares are up 2.25% at $40.00 and the $40.03 high today marks a 52-week high with the new range of the last 52-weeks being $8.78 to $40.03. UPDATE FOR CLOSE: shares closed at $39.64, up 1.3% on 1.11 million shares.

VIVUS Inc. (NASDAQ: VVUS) is seeing a very muted reaction to an analyst research call.  Its shares were initiated with a BUY rating at Needham with a $15.00 price target.  Shares are up a mere 0.8% at $8.94 on 2.1 million shares already in under two hours of trading; the average volume is only 2.4 million shares and the 52-week range is $3.61 to $12.88.  UPDATE FOR CLOSE: shares closed up 2.8% at $9.12 on 4.2 million shares.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Included today is the news, the related share move, performance and valuation data, and added in additional market color where applicable.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now up even more because of a Mike Huckman tout on CNBC.  The gain is due to the board member resignation of Joseph Klein III, a member of the board since June 2005, with disagreements over matters such as a poison pill and other issues.  This has some thinking of a takeover.  Shares were up 5% before the tout, but shares are now up 7.5% at $24.73 on 2.4 million shares.  Average volume is 1.34 million shares and the new 52-week high was hit today of $24.99.

CombinatoRx, Incorporated (NASDAQ: CRXX) is up today after it managed to turn in a profit of $25.2 million during the Q4-2009 period and after it is focusing its R&D efforts.  Shares are up just over 10% at $1.39 on 6.9 million shares.  We saw a high of $1.53 today and the 52-week range is $0.49 to $2.60.  Average volume is only 2.2 million shares.

Electro-Optical Sciences, Inc. (NASDAQ: MELA) is not a biotech but may play a key role in melanoma down the road.  It is down after the company has received additional questions from the FDA over the pre-market approval application of the MelaFind device for early melanoma detection.  The long and short is that the FDA said that its application is not currently approvable and the FDA has now extended the review by up to 180 days. Shares are down 22% at $7.07, but we had seen a low of $6.43 earlier this morning.  There have now been more than 3 million shares traded and average volume is only about 260,000 shares.

Genzyme Corporation (NASDAQ: GENZ) is feeling the wrath of the markets again after yesterday’s FDA action on the Allston plant.  This morning, its shares were Downgraded to Underweight at JPMorgan.  The beatings will continue until morale improves! Shares are down 7.4% at $51.21 and we have seen 9.9 million shares trade hands versus an average of 2.8 million shares.

Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) was awarded FDA approval for Xifaxan 550mg tablets for the risk reduction of overt hepatic encephalopathy recurrence in patients aged 18 and higher.  This is expected to add to sales of the drug.  Shares are off highs of $38.00 earlier with a gain of 8.85% at $36.49 on 4.55 million shares in late morning.  Average volume is about 1.4 million, but this marks a new 52-week high with anything above $34.38.

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is up after last night’s announcement that ondansetron RapidFilm(TM) received approval in 16 European countries.  This is a serotonin 5-HT3 receptor antagonist commonly used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery.  The company expects these EU approvals to support efforts to gain regulatory approval in China, Vietnam, Hong Kong, and Macau.  Shares are up 11.4% at $4.11 on 1.6 million shares.  Average volume is only 450,000 shares and the 52-week trading range is $1.21 to $5.33; its market cap is only $194 million and the company is now profitable.

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) is up again on no news, but this is ahead of its planned 4 million share secondary offering which should price today after the close.  Our bet is that the 4 million shares is more like 4.5 million or maybe even 5 million shares.  This is rare to hear, but this is actually a good version of dilution as it adds much-needed growth capital.  Shares are up 6.4% at $9.83 on 8 million shares.

Warner Chilcott plc (NASDAQ: WCRX) may be on its way for a dividend payment and may still be on the way to becoming the next great emerging drug company.  But its news from yesterday about it closing the former P&G office in Ohio as part of the 2009 acquisition has at least some of the bulls questioning its growth.  This will send 163 American workers to the weekly jobless claims line.  The Irish pharma stock is down 4.4% at $25.54 on over 2 million shares.  Average volume is 1.4 million shares and the 52-week trading range is $9.64 to $29.24.

The new short interest data for short sellers is out showing the March 15 settlement date versus the February 26 date.  Dendreon Corp. (NASDAQ: DNDN) was the largest outright change and Cell Therapeutics, Inc. (NASDAQ: CTIC) shows part of what caused the recovery… short covering.  The full short interest data is here from BioHealthInvestor.com.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Baidu, Inc. (NASDAQ: BIDU) Raised to Neutral at Credit Suisse.
Calpine Corp. (NYSE: CPN) Raised to Equal Weight at Barclays.
L-1 Identity Solutions (NYSE: ID) Cut to Underweight at JPMorgan.
Macy’s Inc. (NYSE: M) Cut to Hold at Deutsche Bank.
Mirant Corporation (NYSE: MIR) Cut to Underweight at Barclays.
Omnicall Inc. (NASDAQ: OMCL) Raised to Buy at ThinkEquity.
ProLogis (NYSE: PLD) Raised to Neutral at UBS.
RF Micro Devices (NASDAQ: RFMD) Started as Buy at Merriman Curhan Ford.
RRI Energy, Inc. (NYSE: RRI) Cut to Equal Weight at Barclays.
Salix Pharmaceuticals (NASDAQ: SLXP) Started as Buy at Jefferies.
Time Warner Inc. (NYSE: TWX) Raised to Buy at Benchmark.
Vertex Pharmaceuticals (NASDAQ: VRTX) Raised to Outperform at Oppenheimer.

You are invited to join our free daily email distribution list to hear about top analyst upgrades and downgrades, IPOs and secondary offerings, ongoing day trader and options trader alerts, stock and market rumors, Buffett and guru investor news, M&A and more.

JON C. OGG
FEBRUARY 1, 2010

Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is one of the top gainers, up 15%… on positive study data.

Delta Petroleum Corporation (NASDAQ: DPTR) is down almost 8% and should be an active stock like it was last week.

E*Trade Financial Corporation (NASDAQ: ETFC) is up over 5% on an Citi call to “Buy” shares.

First Solar, Inc. (NASDAQ: FSLR) is down over 3% on an analyst cut to Sell.

The Mosaic Company (NYSE: MOS) and Potash Corp. of Saskatchewan (NYSE: POT) are both getting clipped on a key analyst downgrade this morning.

Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) is the biggest gainer this morning with a 50% gain on its key IBS study results.

Sprint Nextel Corp. (NYSE: S) is rallying over 20% on word of a Deutsche Telekom (NYSE: DT) bid coming.  Here wwe noticed the stock is close to resistance, assuming the normal trading takes over after the jump up.

You can join our open email distribution list which goes out several times per week for top day trader alerts, top analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
SEPTEMBER 11, 2009

Citrix Systems (CTXS) Cut to Perform at Oppenheimer.
Comstock Resources (CRK) Cut to Hold at Stifel Nicolaus.
Commercial Vehicle Group (CVGI) Raised to Overweight at JPMorgan.
Healthcare Realty (HR) Raised to Outperform at Morgan Keegan.
InterMune (ITMN) Started as Buy at Merriman Curhan Ford.
Royal Dutch Shell (RDS-B) Cut to Neutral at HSBC.
Salix Pharmaceuticals (SLXP) Started as Buy at Merriman Curhan Ford.
Verisign (VRSN) Raised to Outperform at Credit Suisse.

YRC Worldwide (YRCW) Cut to Sell at Stifel Nicolaus.

Jon C. Ogg
August 12, 2009

• Adobe Systems (ADBE) traded down 2% after beating earnings and slightly raised guidance.
• ATS Medical (ATSI) received FDA approval for AP360 mechanical heart valve.
• Best Buy (BBY) $0.53 EPS vs $0.41 est. and $9.92 Billion revenues vs. $9.45 Billion est.; shares traded up 4%.
• Borg Warner (BWA) trades ex-split to reflect a 2 for 1 stock split today.
• Cherokee (CHKE) retained Goldman, Sachs & Co. to explore strategic alternatives including possible sale of the company.
• Dollar Financial (DLLR) raised fiscal 2008 guidance after formally closing its previously announced acquisition of 82 Florida financial-services stores.
• Eli Lilly (LLY) announced that CEO Sidney Taurel will retire in March 2008.
• First Solar (FSLR) noted as a stock pick with 5-years earnings visibility by Cramer on MAD MONEY.
• Forest Labs (FRX) won FDA approval for its new high blood pressure beta blocker along with Maylan Labs.
• Goldman Sachs (GS) set to report earnings with $6.61 EPS estimate (whisper of $7.00 and higher).
• Natus Medical (BABY) put Q1 guidance $0.09-0.10 vs $0.12 estimate; sees 2008 EPS $0.68 to $0.70 vs. $0.63 estimate.
• MedcoHealth Solutions (MHS) noted as a stock pick with 5-years earnings visibility by Cramer on MAD MONEY.
• Mylan Labs (MYL) won FDA approval for its new high blood pressure beta blocker along with Forest Labs.
• Range Resources (RRC) to replace Tribune in S&P 500 Index on Thursday after close.
• Salix Pharmaceuticals (SLXP) will replace Coherent Inc. (COHR) in the S&P SmallCap 600 after the close TODAY.
• Synovus (SNV) lowered its guidance.
• Thornburg (TMO) reinstated dividend with $0.25 payment, says mortgage uncertainties continue.
• Transocean (RIG) noted as a stock pick with 5-years earnings visibility by Cramer on MAD MONEY.

Jon C. Ogg
December 18, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he produces the SPECIAL SITUATION newsletter and he does not own securities in the companies he covers.